Clinical trial
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
NCT00003677 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003677 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Dolastatin 10 |
| Enrollment | 9 |
| Start date | Feb 1, 1999 |
| Primary completion | Jan 16, 2002 |
| Completion | Jan 16, 2002 |
| First posted | Jul 22, 2004 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: